(MENAFN- PR Newswire)
VALENCIA, Spain, May 29, 2025 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced today its participation in the 2025 Jefferies Global Healthcare Conference, being held June 3-5, 2025.
Frédéric Legros, Executive Chairman and CEO, will participate in one-on-one meetings with investors during the conference.
About ARTHEx Biotech
ARTHEx Biotech is a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression. The Company's lead investigational compound, ATX-01, is being evaluated for the treatment of myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I-IIa ArthemiRTM trial. ARTHEx is also advancing its in-house discovery engine to identify and develop microRNA modulators for other disorders with high unmet medical needs, including genetically-driven diseases like DM1. The Company headquarters are in Valencia, Spain.
For more information, please visit and engage with us on LinkedIn.
| Company Contact. |
Investor and Media Contact |
| Frédéric Legros
Executive Chairman and CEO
[email protected]
+33679495790 |
Amy Conrad
Juniper Point
[email protected]
+1 858-366-3243 |
SOURCE ARTHEx Biotech
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
MENAFN29052025003732001241ID1109609281
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment